Treatment challenges of 2 nd /3 rd line HIV/AIDS, hepatitis-C in Seychelles BY DR LOUINE MOREL.

Slides:



Advertisements
Similar presentations
Group III: Demand Forecasting
Advertisements

Harmonization of donor reporting requirements for antiretrovirals and related drugs Presented at the WHO meeting, Geneva ( October 2005) Oteba Olowo.
Contribution of Economics to Operational Research for Evaluation of Scaling Up Access to HIV Care & Treatment in Developing Countries Presentation by Pr.
HIV/AIDS DEPARTMENT 2013 Consolidated ARV Guidelines Treatment Recommendations for Pregnant and Breastfeeding Women: Critical Issues Dr. Nathan Shaffer.
ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.
BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
Dr Tin Tin Sint Department of HIV/AIDS World Health Organization
Rakai Health Sciences Program (RHSP) Uganda Population-based Research on HIV, other Infectious Diseases, Reproductive Health and Service delivery.
Fabio Mesquita, MD, PhD Director of the Brazilian Ministry of Health’s HIV/AIDS and Viral Hepatitis Department July 20th, 2014 Evidence.
Dr R.Reesaul Chest Physician Chest Clinic P. D`or Hospital
The Role of the IATT Optimal Paediatric ARV Formulary and Considerations for New Product Introduction Nandita Sugandhi, M.D. Clinton Health Access Initiative.
Factors Associated With Survival of HIV/HBV Co-infected Patients in Uganda By Ruth Atuhaire Makerere University Business School,
HIV/AIDS and Substance Use Disorders Olivera J. Bogunovic, M.D. State University of New York at Buffalo Alcohol Medical Scholars Program.
Module 6: Treatment options. Module goal To enable participants understand the best current treatment options, factors that influence outcomes and potential.
Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.
Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.
One SADC, One Vision, One Way Working Together Towards MDG 6: SADC’s Common Vision Hon. Benedict Xaba, Minister of Health of Swaziland International AIDS.
PMTCT at Different Levels of Care: The Uganda Experience Dr. Saul Onyango National PMTCT Coordinator Ministry of Health 1 1.
Downloaded from Accelerate scaling up of TB/HIV activities in Tanzania Dr. N.G.SIMKOKO WHO/NTLP - Tanzania.
Larry Cuellar Adult Viral Hepatitis Prevention Coordinator Texas Department of State Health Services 2010 STREET OUTREACH WORKERS CONFERENCE June 21, 2010.
HIV Treatment and Care Research priorities Facilitator – Dr Saphonn Vonthanak 12 participants 29 agreed topics –not grouped on methodology or subject category.
1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
Nov 2004Access to Paediatric ARV formulations ENSURING SECURE and RELIABLE SUPPLY and DISTRIBUTION SYSTEMS in DEVELOPING COUNTRIES, in the CONTEXT OF HIV/AIDS.
6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,
Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.
Orientation on HIV care and ART Recording and Reporting System.
BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.
Antiretroviral Treatment Monitoring: A Canadian Case Example Antiretroviral Treatment Monitoring: A Canadian Case Example Robert Hogg, PhD BC Centre for.
Task Shifting in Malawi around delivery of antiretroviral therapy Anthony D Harries “The Union” Paris, France.
Downloaded from Current Status of ART Opportunities & Challenges Kibrebeal Melaku,MD Associate Professor.
I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
Antiretroviral Pharmacovigilance Training Course Dar es Salaam, United Republic of Tanzania 23 rd – 28 th November 2009.
Prevention of Mother to Child HIV Transmission Dr. Laura Guay Vice President for Research Elizabeth Glaser Pediatric AIDS Foundation July 15, 2009 Cape.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.
The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,
‘Gaps in the global HIV/AIDS success story Copenhagen December 2 nd 2013 Gaps in the global HIV/AIDS success story Briefing on HIV/AIDS in Europe Martin.
President’s Emergency Plan for AIDS Relief 2006 Semi-Annual Program Results (SAPR) October 1, 2005 – March 31, 2006.
Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.
Mary Lawrence Hicks, FNP Positive Health Program October 21, 2010.
SPECIAL CONSIDERATIONS August
PERSPECTIVES FROM THE FIELD DR LYDIA MUNGHERERA TASO (The Aids Support Organisation) UGANDA REVERSING THE TIDE OF TB.
Sub module 1 Introduction to HIV care and ART recording and reporting system.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Fast-Tracking Treatment to End AIDS ICASA Ambassador Deborah Birx, MD U.S. Global AIDS Coordinator November 30, 2015.
ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.
Hepatitis C and Sexual & Reproductive Health Graham Mackintosh, Training & Capacity Officer Lesley Bon, Patient Involvement Officer.
Outcome of a Prevention of mother to child transmission (PMTCT ) programme following Implementation of prophylaxis for HIV infected pregnant women in Barbados:
Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,
Learning objectives Review HIV treatment goals
Learning objectives Define HIV treatment goals
Facility Community Linkages
Community ART delivery models for high patient’s retention and good
The Debswana Anti Retroviral Therapy Programme
Cross-sectional assessment of patient outcomes using a systematic file review process: Results from 12,987 patient files Ambereen Jaffer, Gesine Meyer-Rath,
Utilizing research as an opportunity to strengthen
VL patient support: General education at different levels
Knowledge gaps in formulating TB Control Policies for Prisons
Charles Gilks HIV Department, WHO
Serge Masyn Director, Johnson & Johnson Global Public Health
How it was possible to offer Integrase Inhibitor as first line ART while maintaining the sustainability of the Brazilian policy of universal access to.
ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: PROGRESS & CHALLENGES IN SOUTH AFRICA YOGAN PILLAY DEPARTMENT OF HEALTH, SOUTH AFRICA IAS, 2014.
Monitoring of Antiretroviral therapy (ART)delivery by Regional Tuberculosis Officers (RTO) in Malawi: Rhehab Chimzizi Anthony Harries Edwin Libamba Maxwell.
Inventory Management: Distribution, ICS, LMIS
Presentation transcript:

Treatment challenges of 2 nd /3 rd line HIV/AIDS, hepatitis-C in Seychelles BY DR LOUINE MOREL

Presentation outline Local Situation Treatment availability Advantages Challenges Way forward

Local Situation (source MOH Seychelles) SUMMARY HIV & AIDS FROM 1987 TO JUNE 2014 Cumulative HIV Cases 608 (356M/252F) Cumulative AIDS Cases 267 (165M/102F) Cumulative Deaths 125 (75M/50F) Cumulative HIV Positive Pregnancies 103 Living with HIV & AIDS 397 (226M/171F)

Cases on HAART 228 (124M/104F) Left Seychelles 86 (55M/31F) Cumulative Loss to Follow-Up cases 80 (53M/27F) Cumulative Drop-Outs on HAART 36 (19M/17F) Defaulter on treatment (>3 months) representing 14% of the HIV & AIDS clients eligible for treatment as per WHO recommended guidelines.

HEPATITIS C Since 2002 to June 2014 a cumulative of 440 cases of Hepatitis C of which 360(82%) were males and 80(18%) were females. Out of the 440 cases, 36 (27M/9 F) had HIV and Hepatitis C Co-infection and 13 (7M/6F) Hepatitis C related deaths. 99% of cases are injecting drug users. Minimal access to services Poor uptake on the Hepatitis B vaccination program

Treatment availability Antiretroviral 1 st Line(NNRTI Base): 38% 2 nd line(Protease Inhibitor base): 62% 3 rd Line: 0% 397 PLWHIV: 60% on treatment

Treatment Availability Hepatitis C management No treatment available Interferon gamma used for other diseases NO RIBAVIRIN at the moment Follow-up of Hepatitis C patients: Blood test 2 time per year/ Annual Liver Ultrasound Laboratories facilities: ill equipped: No genotyping no viral load available R50million needed to treat Hepatitis C(calculated end 2013)

Advantages No stock rupture One distribution point Quarterly monitoring of patient outcomes and ARV drug stocks 90% of patients on ART viral load undetectable Only 14% drop out on ART Resistance testing done: Minimal resistance One patient to this date resistant to all available ART in Seychelles

An overview of the challenges involved in ART drug management Increased number of different ARV formulations Increases the risk of stock outs Keeping the number of different ARV formulations as small as possible while maintaining adequate treatment options for the vast majority of patients Correctly forecasting the proportion of patients in need of changing of ART regimen Balancing minimum order v/s wastage

Ensure that adequate alternative and second-line ARVs are available (switching ARV regimens) Storage capacity in health facilities is limited Increase frequency of deliveries of ART to outer islands Similar challenges faced with the treatment for opportunistic infections LIMITED paediatric formulation ABACAVIR initiation FREE ART: Sustainability

Way forward Adopting 90% treatment target: As a means to reduce infection Increase usage of ABACAVIR Purchasing 3 rd line regimen Investing in fix dose regimen Stocking of ARVs on outer islands COST: SUSTAINING cost of ART

Thank you!